Obseva SA, of Geneva, said its board approved an increase of its share capital from 45.5 million shares to 48.6 million. The shares will be listed on the SIX Swiss Exchange on or around July 23.
Eyenovia Inc., of New York, said it closed its underwritten public offering of 4.38 million shares of common stock at $2.78 each for net proceeds of approximately $11.2 million.
Valeo Pharma Inc., of Montreal, said it filed its final short form prospectus in each of the provinces and territories of Canada in connection with its sale of a minimum of 4 million units and a maximum of 16 million units at CA50 cents each for gross proceeds of between CA$2 million (US$1.53 million) and CA$8 million (US$6.13 million).
Horizon Therapeutics plc, of Dublin, said Horizon Pharma U.S. Inc., its wholly owned subsidiary, priced its offering of $600 million aggregate principal amount of 5.5% senior notes due 2027.
Hemostemix Inc., of Calgary, Alberta, said it will not proceed with its nonbrokered private placement of up to $6 million in secured convertible debentures and will not have a second close of its nonbrokered private placement of up to $1 million in secured convertible debentures, which previously raised gross proceeds of $525,000. The company said it continues to pursue efforts to raise capital to fund operations and an ongoing phase II trial.
Hummingbird Bioscience Pte. Ltd., of Singapore, said it completed an extended series A financing round led by Heritas Capital Management and SEEDS Capital, the investment arm of Enterprise Singapore.
GNS Healthcare Inc., of Cambridge, Mass., said it raised $23 million in a series D fundraising led by Cigna Ventures, a wholly owned indirect subsidiary of Cigna Corp., with participation from Amgen Ventures, Celgene Corp., Echo Health Ventures, Alexandria Venture Investments and former Caesar's CEO and Aetna Division President Gary Loveman.
Oncosenx Inc., of Seattle, said it raised $3 million in pre-seed funding to advance its pipeline. The company is developing a selective tumor-killing platform with two main components: a proprietary lipid nanoparticle for cellular delivery and a selective DNA payload.
Algernon Pharmaceuticals Inc., of Vancouver, British Columbia, said it expects to raise between CA$2.5 million (US$1.9 million) and CA$5 million in a best efforts public offering of an undisclosed number of units intended to support up to three phase II trials.
